

NAVIGATING THE PATIENT JOURNEY IN CHRONIC LYMPHOCYTIC LEUKEMIA

Oncology Nurse Strategies
in Therapy Management

Presented by Creative Educational Concepts, Inc.

Supported through an independent educational grant from AstraZeneca.



Faculty



Barbara Rogers CRNP, MN, AOCN, ANP-BC
Adult Hematology-Oncology Nurse Practitioner
Fox Chase Cancer Center
Philadelphia, Pennsylvania



Shazia K Nakhoda, MD
Assistant Professor, Department of
Hematology/Oncology
Fox Chase Cancer Center
Philadelphia, Pennsylvania

Special Thanks!

Presented by



Supported through an independent educational grant from AstraZeneca.

CNE Certification



This activity is approved for up to 1 ANCC contact hour.

Faculty Disclosures

In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Planners:

Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Katherine L. Byar, MSN, ANP-BC, BMTCN—has no relevant financial relationships to disclose in relation to the content of this activity.

Matthew Lunning, DO—has disclosed that he is a consultant for Acrotech, ADC Therapeutics, AstraZeneca, BeiGene, BMS, Daiichi Sankyo, Janssen, Karyopharm, Kite, Kyowa Kirin, Legend, Morphosys, Myeloid Therapeutics, Novartis, Spectrum, and TG Therapeutics.

Authors/Presenters:

Katherine L. Byar, MSN, ANP-BC, BMTCN—has no relevant financial relationships to disclose in relation to the content of this activity.

Ian W. Flinn, MD, PhD—has disclosed that he is a consultant for AbbVie, AstraZeneca, BeiGene, Genentech, Gilead Sciences, Great Point Partners, Iksuda Therapeutics, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Novartis, Nurix Therapeutics, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem, Vincerx Pharma, and Yingli Pharmaceuticals but his honorarium is issued to his institution, Sarah Cannon Research Institute. He receives grant/research support from AbbVie, Acerta Pharma, Agios, ArQule, AstraZeneca, BeiGene, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, Forma Therapeutics, Forty Seven, Genentech, Gilead Sciences, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Janssen, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Loxo, Merck, MorphoSys, Novartis, Pfizer, Pharmacyclics, Portola Pharmaceuticals, Rhizen Pharmaceuticals, Roche, Seattle Genetics, Takeda, Teva, TG Therapeutics, Trillium Therapeutics, Triphase Research & Development Corp., Unum Therapeutics, and Verastem but his honorarium is issued to his institution, Sarah Cannon Research Institute.

Amy L Goodrich, RN, MSN, CRNP-AC—has disclosed that she is a consultant/on the advisory board for Abbvie, AstraZeneca, Celgene, and Rigel.

Matthew Lunning, DO—has disclosed that he is a consultant for Acrotech, ADC Therapeutics, AstraZeneca, BeiGene, BMS, Daiichi Sankyo, Janssen, Karyopharm, Kite, Kyowa Kirin, Legend, Morphosys, Myeloid Therapeutics, Novartis, Spectrum, and TG Therapeutics.

Shazia K. Nakhoda, MD—has no relevant financial relationships to disclose in relation to the content of this activity.

Barbara Rogers, CRNP, MN, AOCN, ANP-BC—has disclosed that she is a consultant for ADCC Therapeutics, Cardinal Health, and Coherus. She is on the speakers' bureau for AstraZeneca and Coherus.

Julie Vose, MD, MBA—has disclosed that she is a consultant for Abbvie, Acerta Pharma/AstraZeneca, Conjupro Biotherapeutics, Genentech, Janssen/Pharmacyclics, Johnson and Johnson, Kite Pharma, Morphosys, Oncernal, Roche, and Vaniam Group. She receives grant/research support from Acerta Pharma/AstraZeneca, Celgene/BMS, Epizyme, Incyte Corp., Kite Pharma, LOXO, Novartis, and Seattle Genetics, Inc.

Reviewer:

Beth Faiman, PhD, MSN, APRN-BC, AOCN, FAAN—has no relevant financial relationships to disclose in relation to the content of this activity.

Learning Objectives

- Review the role of the BCR (B-cell receptor) pathway in CLL development and examine currently available and emerging novel therapies targeting the BCR pathway.
- Appraise the appropriate selection and sequencing of CLL therapy based on current guideline recommendations and patient-specific factors, such as line and duration of therapy, clinical presentation, mutation status, among others.
- Discuss unique differences between novel therapies, strategies to properly monitor and manage toxicities, and key counseling points to discuss with patients to ensure minimization of toxicities and optimization of oral adherence.
- Explore strategies to ensure patient understanding and empowerment about the treatment plan and ways to encourage open communication between patient and provider to optimize outcomes.